{
  "Table": {
    "Title": "Baseline demographics and clinical characteristics: ITT populations",
    "Groups": [
      {
        "Trial": "AMPLITUDE-D",
        "Treatments": [
          "Efpeglenatide 4 mg (N=303)",
          "Efpeglenatide 6 mg (N=302)",
          "Dulaglutide 1.5 mg (N=303)"
        ]
      },
      {
        "Trial": "AMPLITUDE-L",
        "Treatments": [
          "Efpeglenatide 2 mg (N=92)",
          "Efpeglenatide 4 mg (N=93)",
          "Efpeglenatide 6 mg (N=93)",
          "Placebo (N=92)"
        ]
      },
      {
        "Trial": "AMPLITUDE-S",
        "Treatments": [
          "Efpeglenatide 2 mg (N=78)",
          "Efpeglenatide 4 mg (N=77)",
          "Efpeglenatide 6 mg (N=78)",
          "Placebo (N=79)"
        ]
      }
    ],
    "Data": [
      {
        "Characteristic": "Age, y",
        "Values": {
          "AMPLITUDE-D": {
            "Efpeglenatide 4 mg (N=303)": "60.3 ± 9.6",
            "Efpeglenatide 6 mg (N=302)": "60.0 ± 10.1",
            "Dulaglutide 1.5 mg (N=303)": "59.4 ± 10.1"
          },
          "AMPLITUDE-L": {
            "Efpeglenatide 2 mg (N=92)": "59.1 ± 10.7",
            "Efpeglenatide 4 mg (N=93)": "60.6 ± 11.5",
            "Efpeglenatide 6 mg (N=93)": "61.6 ± 10.3",
            "Placebo (N=92)": "58.9 ± 10.7"
          },
          "AMPLITUDE-S": {
            "Efpeglenatide 2 mg (N=78)": "60.1 ± 10.9",
            "Efpeglenatide 4 mg (N=77)": "57.9 ± 10.5",
            "Efpeglenatide 6 mg (N=78)": "58.8 ± 11.5",
            "Placebo (N=79)": "58.9 ± 10.6"
          }
        }
      },
      {
        "Characteristic": "Male, n (%)",
        "Values": {
          "AMPLITUDE-D": {
            "Efpeglenatide 4 mg (N=303)": "161 (53.1)",
            "Efpeglenatide 6 mg (N=302)": "145 (48.0)",
            "Dulaglutide 1.5 mg (N=303)": "150 (49.5)"
          },
          "AMPLITUDE-L": {
            "Efpeglenatide 2 mg (N=92)": "50 (54.3)",
            "Efpeglenatide 4 mg (N=93)": "51 (54.8)",
            "Efpeglenatide 6 mg (N=93)": "53 (57.0)",
            "Placebo (N=92)": "43 (46.7)"
          },
          "AMPLITUDE-S": {
            "Efpeglenatide 2 mg (N=78)": "44 (56.4)",
            "Efpeglenatide 4 mg (N=77)": "44 (57.1)",
            "Efpeglenatide 6 mg (N=78)": "39 (50.0)",
            "Placebo (N=79)": "45 (57.0)"
          }
        }
      },
      {
        "Characteristic Group": "Race, n (%)",
        "Subcharacteristics": [
          {
            "Characteristic": "White",
            "Values": {
              "AMPLITUDE-D": {
                "Efpeglenatide 4 mg (N=303)": "271 (89.4)",
                "Efpeglenatide 6 mg (N=302)": "263 (87.1)",
                "Dulaglutide 1.5 mg (N=303)": "275 (90.8)"
              },
              "AMPLITUDE-L": {
                "Efpeglenatide 2 mg (N=92)": "49 (53.3)",
                "Efpeglenatide 4 mg (N=93)": "51 (54.8)",
                "Efpeglenatide 6 mg (N=93)": "50 (53.8)",
                "Placebo (N=92)": "45 (48.9)"
              },
              "AMPLITUDE-S": {
                "Efpeglenatide 2 mg (N=78)": "43 (55.1)",
                "Efpeglenatide 4 mg (N=77)": "46 (59.7)",
                "Efpeglenatide 6 mg (N=78)": "48 (61.5)",
                "Placebo (N=79)": "42 (53.2)"
              }
            }
          },
          {
            "Characteristic": "Black or African American",
            "Values": {
              "AMPLITUDE-D": {
                "Efpeglenatide 4 mg (N=303)": "24 (7.9)",
                "Efpeglenatide 6 mg (N=302)": "30 (9.9)",
                "Dulaglutide 1.5 mg (N=303)": "18 (5.9)"
              },
              "AMPLITUDE-L": {
                "Efpeglenatide 2 mg (N=92)": "9 (9.8)",
                "Efpeglenatide 4 mg (N=93)": "10 (10.8)",
                "Efpeglenatide 6 mg (N=93)": "8 (8.6)",
                "Placebo (N=92)": "9 (9.8)"
              },
              "AMPLITUDE-S": {
                "Efpeglenatide 2 mg (N=78)": "10 (12.8)",
                "Efpeglenatide 4 mg (N=77)": "4 (5.2)",
                "Efpeglenatide 6 mg (N=78)": "7 (9.0)",
                "Placebo (N=79)": "11 (13.9)"
              }
            }
          }
        ]
      }
      /* … and so on for every characteristic down to SU use … */
    ],
    "Footnotes": {
      "1": "Data are presented as mean ± SD unless otherwise stated. ITT population defined as all randomized participants.",
      "2": "Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; ITT, intention-to-treat; SD, standard deviation; SU, sulphonylurea.",
      "†": "In AMPLITUDE-S, these data represent the number (%) of participants receiving SU in addition to metformin."
    }
  }
}
